







































ditorialheumatoid  arthritis  and  metabolic  syndrome
 artrite  reumatoide  e  a  síndrome  metabólicacientiﬁc research on rheumatoid arthritis (RA) led to the
rafting of recommendations on early diagnosis of articular
anifestations, appropriate measurements of inﬂammatory
ctivity and bone damage, and target-based treatment, which
ere consolidated in similar guidelines from various organiza-
ions such as the Sociedade Brasileira de Reumatologia (SBR),
he American College of Rheumatology (ACR) and the Euro-
ean League Against Rheumatism (EULAR).1–4 To the extent
hat the treatment strategies of joint manifestations have
xpanded in terms of options and effectiveness, a greater
oncern has arisen about associated diseases, particularly
ardiovascular disease (CVD), which became the main respon-
ible for the decrease of survival in this population, despite
igniﬁcant advances in drug therapy.5–7
Currently, an earlier investigation and monitoring of tradi-
ional risk factors for CVD is recommended, since its presence
s associated with an increased clinical activity of RA, with a
orse prognosis, and with doubling of CVD risk.8–13
The chronic inﬂammatory state, coupled with limited
obility, a sedentary lifestyle and the use of Nonsteroidal anti-
nﬂammatory drugs (NSAIDs) and corticosteroids, determines
he activation of several harmful mechanisms for circulation
nd also increases the predisposition to metabolic syndrome
MS).7,8,11,14
RA and MS share pathogenic mechanisms, for example,
n increase in free radicals, a deﬁciency of antioxidant sys-
ems, an increase in pro-inﬂammatory cytokines, endothelial
njury, and the formation and destabilization of atheroscle-
otic plaques.8,9,15
The concept of MS  arose in the 1980s, encompassing central
besity, dyslipidemia, systemic hypertension and hyper-
lycemia/insulin resistance as elements that are enhanced
nd that, together, offer a higher risk of CVD than the sum of
ndividual factors. The literature has evolved with the study
f MS in different populations, until the proposition of uniﬁed
riteria in 2009.16,17Although the identiﬁcation of MS  in patients with RA is
ery variable, depending on the populations studied and the
lassiﬁcation criteria used, its prevalence has increased anddetermines an additional risk of CVD.5,15,18 A better knowl-
edge of the prevalence of MS and its associations in different
groups of patients results in subsidies to improve preventive
strategies.
In this issue, Oliveira et al. evaluated the occurrence of
MS in patients with RA followed in a university hospital in
northeastern Brazil. In this sample, with large female predom-
inance, more  than half of the patients fulﬁlled different MS
criteria. In addition to obesity, present in almost all patients
with MS, there was an association with other risk factors, such
as age and smoking.19 These ﬁndings point to a high risk of
CVD and increased mortality.
The scientiﬁc community still discuss whether the assess-
ment for risk of CVD should be carried out by instruments used
in the general population, or by tools adapted for RA, to enable
a more  reliable risk assessment, in order to reduce morbidity
and mortality.20,21
With this goal, de Campos et al. tested a tool for prediction
of cardiovascular events, modiﬁed for use in patients with RA
– the mSCORE index. The study evaluated 100 female subjects
with RA versus controls without the disease; it was observed
that there was no difference between groups with respect to
the results of the original SCORE index. However, with the use
of mSCORE version, which includes factors speciﬁc to the dis-
ease, a 3-fold increase in the number of subjects classiﬁed as
of high risk was found, thus becoming clear the increased risk
of the occurrence of a 10-year fatal cardiovascular event in
patients with RA.22
This study emphasizes the fact that, during a systematic
evaluation of patients with RA, an evaluation of cardiovascu-
lar risk must also be carried out. Moreover, this assessment
should be performed with valid instruments, allowing the
identiﬁcation of the risk of CVD and pointing to therapeutic
targets, in order to perform earlier and more  efﬁcient inter-
ventions.
In this way, one can make a better use of the acknowledged
advances in the treatment of joint disease in these patients,
in order to obtain, for them, a better and long-lasting health
condition.
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